03.02.2010 • News

Millipore Q4 Beats Wall Street View

Millipore, a maker of purification systems used in drug manufacture, posted a better-than-expected
quarterly profit, helped by higher revenue from its bioprocess division.

Net income for the fourth quarter was about $44 million, or 78 cents a share, compared with $31.1 million, or 56 cents a share, in the year-ago quarter. Excluding items, the company posted earnings of $1 per share,
Millipore said in a statement. Revenue for the quarter rose 7% to $426 million.

Analysts on average expected the company to earn 94 cents a share, excluding items, on revenue of $421.5 million, according to Thomson Reuters I/B/E/S. Bioprocess division sales rose 9%, helped by strong
demand from the company's biotechnology customers and higher levels of vaccine production, Chief Executive Martin Madaus said.

Company

Millipore Corporation

17 Cherry Hill Drive
01923 Danvers

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read